DEF 14C: International Isotopes Rebrands to Radnostix, Inc.
Information Statement Name Change
International Isotopes Inc. is changing its corporate name to Radnostix, Inc. to reflect its strategic shift towards radiopharma and theranostics in healthcare.
Summary
- International Isotopes Inc. will change its corporate name to Radnostix, Inc. to better reflect its expanded business focus.
- The company's Board of Directors unanimously approved the Name Change on October 21, 2025.
- Shareholders representing 52.1% of the voting power (275,232,379 out of 528,209,538 outstanding shares) approved the Name Change by written consent on November 25, 2025.
- The strategic shift involves expanding from radiochemicals and non-medical radioisotopes for the energy sector to a broader portfolio of radioisotope, theranostics, and related products, devices, and accessories primarily focused on healthcare applications.
- Management believes this new focus on radiopharma and theranostics offers new opportunities that could lead to greater profits over the next twelve months and in the long term.
Sentiment
Score: 7
Explanation: The name change reflects a strategic pivot towards a high-growth sector (radiopharma and theranostics) with management explicitly stating expectations for greater long-term profits. This indicates a positive strategic direction, though it's an informational filing, not a performance report.
Positives
- Strategic pivot towards the high-growth radiopharma and theranostics business, which management believes offers significant new opportunities.
- Expectation of achieving greater profits over the next twelve months and in the long term due to the new business focus.
- Unanimous approval by the Board of Directors for the strategic direction and name change.
Future Outlook
The Board believes that the new opportunities available in the radiopharma and theranostics business could enable the company to achieve greater profits over the course of the next twelve months and in the long term.
Management Comments
- Our line of business has expanded from providing radiochemicals and non-medical radioisotopes and a focus on energy-sector relate isotopes to providing a broader portfolio of radioisotope, theranostics, and related products, devices, and accessories, mainly focused on healthcare applications.
- Our Board decided to change our business focus because it has identified new opportunities available to us in the radiopharma and theranostics business.
- Our Board believes that these opportunities could enable us to achieve greater profits over the course of the next twelve months and in the long term than we would be able to achieve if we continued to carry out our current line of business.
- We believe that the name International Isotopes Inc. no longer completely describes the business activities that we now engage in.
Industry Context
The company's strategic shift towards radiopharma and theranostics aligns with a growing trend in the healthcare industry, where these specialized medical isotopes and diagnostic/therapeutic agents are seeing increased demand for advanced disease detection and treatment. This move positions the company to capitalize on a high-growth segment, moving away from a more generalized energy-sector focus.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Certificate of Formation Amendment | Amendment to Article I of the Restated Certificate of Formation to change the corporate name from International Isotopes Inc. to Radnostix, Inc. | On or about December 22, 2025 | Formalizes the corporate name change to align with the new strategic business focus. |
Stakeholder Impact
- Shareholders: Will receive an information statement regarding the name change; existing stock certificates remain valid; potential for increased long-term value if the strategic shift to radiopharma and theranostics proves successful.
- Customers: Implies a shift in product offerings and focus towards healthcare applications, potentially expanding the customer base in radiopharma and theranostics.
- Employees: Implies a shift in business focus which may lead to changes in skill requirements or operational structure, though not explicitly stated.
Next Steps
- The Information Statement will be mailed to shareholders on or about December 2, 2025.
- The Certificate of Amendment will be filed with the Secretary of State of the State of Texas.
- The Name Change will become effective on or about December 22, 2025.
- New stock certificates will be issued bearing the new name in the future, though current certificates remain valid.
Key Dates
| Date | Description |
|---|---|
| 1995-11-01 | Date of formation of International Isotopes Inc. |
| 2010-01-21 | Date of the Restated Certificate of Formation of International Isotopes Inc. |
| 2025-10-21 | Board of Directors unanimously approved the Name Change. |
| 2025-11-24 | Record Date for determining shareholders entitled to vote on the Name Change; 528,209,538 shares of Common Stock outstanding. |
| 2025-11-25 | Majority shareholders (52.1% of voting power) approved the Name Change by written consent. |
| 2025-11-26 | Date of the Information Statement. |
| 2025-12-02 | Anticipated date the Information Statement is first mailed to shareholders. |
| 2025-12-22 | Anticipated effective date of the Name Change (at least 20 calendar days after mailing of Information Statement). |
Recommendation
holdThe company is undertaking a strategic name change to reflect a pivot towards the high-growth radiopharma and theranostics sector, which management anticipates will lead to greater profits. While this strategic direction is positive, the filing is purely informational and does not provide financial results or detailed operational plans for the new focus. Investors should hold to observe the execution of this new strategy and await future financial disclosures that demonstrate tangible progress and profitability in the new market segments.
Keywords
Radnostix, International Isotopes, Name Change, Radiopharma, Theranostics, Healthcare Isotopes, Medical Devices, Radioisotopes, Corporate Rebranding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.